Linguistic strategies for professional politeness among aspiring managers: An analysis of organizational psycholinguistics

In order to effectively communicate in a professional setting, it is essential for managers to have a mastery of the language specific to their field. One tool that can be used for professional communication is verbal politeness, which involves using appropriate words and phrases to show respect for the listener and soften unfavourable information. These linguistic units promote a culture of professionalism and ethical business relationships and are a key indicator of a manager's speech competence. A psycholinguistic study examined the usage of polite language by aspiring managers. The participants were 218 undergraduate and graduate students enrolled in the Management program across various universities in Ukraine's oblasts. The organizational psycholinguistics research aimed to assess the extent to which aspiring managers incorporate professional language units such as polite words and phrases in their speech. We analyzed the references of 1,308 respondents to determine how politeness language units corresponded to the structural parts of the document. By studying 928 selected language units of politeness, we could assess the level of politeness markers. This indicator reflects future managers' skill level in applying synonymous ranges of politeness. The analysis found that respondents used various linguistic units to soften the impact of unfavourable information when conveying it to others. These units formed synonymous ranges based on context and semantic content. Only half of the students showed a wide range of knowledge and skills in appropriately using polite language. Thus, aspiring managers need to improve their knowledge and practical skills in using a variety of linguistic units of politeness in business documents. Therefore, we recommend implementing programs to improve communication levels for those pursuing higher education in management. Disclosure Statement No potential conflict of interest was reported by the authors. * Corresponding author: Olena Vlasenko, 0000-0002-1011-1965 [email protected]

The Importance of the Cultural and Religious Components in Higher Education

During the study, the analytical and bibliographic method was applied to study the scientific literature on cultural and religious education and a questionnaire survey to practically investigate individual aspects of the cultural and religious component in higher education. As a result of the study, we have been studied the opinions of scholars concerning individual problematic issues and the significance of the cultural and religious component in higher education; the viewpoints of students and professionals, performing scientific and pedagogical activities in the sphere of religious studies, on the influence and role of spiritual culture on the level of cultural and aesthetic development of students

Evaluación del Índice de Similaridad de Exportación compuesta sobre el Ejemplo de China

El propósito de este artículo es mejorar el Índice de similitud de exportación para proporcionar resultados más confiables sobre si dos países son competidores potenciales e inmediatos en el comercio mundial y en qué medida. Para lograr esta metodología existente se complementó con el conjunto de destinos geográficos. Esto permite evaluar la superposición de las carteras de exportación de dos o más países y comprender el posible nivel de su competencia en el comercio internacional. Para demostrar la eficiencia de este índice mejorado, se comparó la cartera de exportaciones de China con los 50 mayores exportadores. Los resultados obtenidos demuestran una fuerte superposición del comercio chino con Vietnam, Japón y Filipinas, lo que demuestra la veracidad de la metodología introducida

Thermophysiological comfort properties of textile shields against EMR

Investigation of the influence of structure and composition of hybrid fabric shields against EMR on the ability to provide thermophysical comfort

Multilevel transfer of innovations: Cognitive modeling to decision support in managing the economic growth

An essential aspect of the country’s economic growth is the transfer of innovation, which is very important nowadays. The innovative projects can be implemented through it at the level of households, companies, institutions, and local communities. The transfer of innovations is intended to cause a cumulative effect and stimulate economic growth. It is important to determine the influence of different factors on this process and consider the feedbacks in the “enterprise-region-state” system, which will increase the level of control over the process. The paper aims to find scientific instruments for managing the multilevel transfer of innovations, representing the connections between factors that act as catalysts/inhibitors of that process. The proposed methodology uses systems analysis, indicative analysis, and cognitive modeling (Fuzzy Cognitive Maps (FCM)). Based on the study results, a cognitive model was formed based on identifying the “strength of impact” of connections between elements that determine the level of influence of the micro- and macro-environment factors of the innovation multilevel transfer. From a practical point of view, this allows obtaining forecasts of its behavior under different management actions. To implement the research results, it is necessary to determine management tools that will allow stakeholders in the system “enterpriseregion-state” to make a transfer of innovations most effective. It demonstrates the need for further research in this area and assessing the potential consequences of management decisions for economic growth

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

Aims/hypothesis In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with ertugliflozin compared with placebo as 0.81 (0.63, 1.04). The effect of ertugliflozin on exploratory kidney-related outcomes was evaluated using data from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881). Methods Individuals with type 2 diabetes mellitus and established atherosclerotic CVD were randomised to receive ertugliflozin 5 mg or 15 mg (observations from both doses were pooled), or matching placebo, added on to existing treatment. The kidney composite outcome in VERTIS CV (reported previously) was time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death. The pre-specified exploratory composite outcome replaced doubling of serum creatinine with sustained 40% decrease from baseline in eGFR. In addition, the impact of ertugliflozin on urinary albumin/creatinine ratio (UACR) and eGFR over time was assessed. Results A total of 8246 individuals were randomised and followed for a mean of 3.5 years. The exploratory kidney composite outcome of sustained 40% reduction from baseline in eGFR, chronic kidney dialysis/transplant or renal death occurred at a lower event rate (events per 1000 person-years) in the ertugliflozin group than with the placebo group (6.0 vs 9.0); the HR (95% CI) was 0.66 (0.50, 0.88). At 60 months, in the ertugliflozin group, placebo-corrected changes from baseline (95% CIs) in UACR and eGFR were −16.2% (−23.9, −7.6) and 2.6 ml min−1 [1.73 m]−2 (1.5, 3.6), respectively. Ertugliflozin was associated with a consistent decrease in UACR and attenuation of eGFR decline across subgroups, with a suggested larger effect observed in the macroalbuminuria and Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease (KDIGO CKD) high/very high-risk subgroups. Conclusions/interpretation Among individuals with type 2 diabetes and atherosclerotic CVD, ertugliflozin reduced the risk for the pre-specified exploratory composite renal endpoint and was associated with preservation of eGFR and reduced UACR. Trial registration ClinicalTrials.gov NCT0198688

Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial

Background and objectives A reduction in the rate of eGFR decline, with preservation of $0.75 ml/min per 1.73 m2 per year, has been proposed as a surrogate for kidney disease progression. We report results from prespecified analyses assessing effects of ertugliflozin versus placebo on eGFR slope from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881). Design, setting, participants, & measurements Patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease were randomized to placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg (1:1:1). The analyses compared the effect of ertugliflozin (pooled doses, n55499) versus placebo (n52747) on eGFR slope per week and per year by random coefficient models. Study periods (weeks 0–6 and weeks 6–52) and total and chronic slopes (week 0 or week 6 to weeks 104, 156, 208, and 260) were modeled separately and by baseline kidney status. Results In the overall population, for weeks 0–6, the least squares mean eGFR slopes (ml/min per 1.73 m2 per week [95% confidence interval (95% CI)]) were 20.07 (20.16 to 0.03) and 20.54 (20.61 to 20.48) for the placebo and ertugliflozin groups, respectively; the difference was 20.47 (20.59 to 20.36). During weeks 6–52, least squares mean eGFR slopes (ml/min per 1.73 m2 per year [95% CI]) were 20.12 (20.70 to 0.46) and 1.62 (1.21 to 2.02) for the placebo and ertugliflozin groups, respectively; the difference was 1.74 (1.03 to 2.45). For weeks 6–156, least squares mean eGFR slopes (ml/min per 1.73 m2 per year [95% CI]) were 21.51 (21.70 to 21.32) and 20.32 (20.45 to 20.19) for the placebo and ertugliflozin groups, respectively; the difference was 1.19 (0.95 to 1.42). During weeks 0–156, the placebo-adjusted difference in least squares mean slope was 1.06 (0.85 to 1.27). These findings were consistent by baseline kidney status. Conclusions Ertugliflozin has a favorable placebo-adjusted eGFR slope .0.75 ml/min per 1.73 m2 per year, documenting the kidney function preservation underlying the clinical benefits of ertugliflozin on kidney disease progression in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Clinical Trial registry name and registration number: US National Library of Medicine, ClinicalTrials.gov NCT01986881. Date of trial registration: November 13, 2013

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

BACKGROUND The cardiovascular effects of ertugliflozin, an inhibitor of sodium–glucose cotransporter 2, have not been established. METHODS In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P=0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.)

Інноваційні драйвери національної економічної безпеки: структурне моделювання та прогнозування

Мета роботи – формування методологічних засад та методичного інструментарію моделювання та прогнозування взаємозв’язку інноваційного розвитку суб’єктів господарювання та забезпечення економічної безпеки в Україні, наукове обґрунтування та розробка структурної, формалізованої національної інноваційної стратегії забезпечення економічної безпеки, яка міститиме чіткі алгоритми застосування важелів державного управління, математично формалізовані цільові таргети, та дозволить зменшити вплив системних ризиків в національній економіці

Інноваційні драйвери національної економічної безпеки: структурне моделювання та прогнозування

Мета роботи – формування методологічних засад та методичного інструментарію моделювання та прогнозування взаємозв’язку інноваційного розвитку суб’єктів господарювання та забезпечення економічної безпеки в Україні, наукове обґрунтування та розробка структурної, формалізованої національної інноваційної стратегії забезпечення економічної безпеки, яка міститиме чіткі алгоритми застосування важелів державного управління, математично формалізовані цільові таргети, та дозволить зменшити вплив системних ризиків в національній економіці